IRulya Therapeutics Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 04 Sep 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 20 Mar 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 01 Apr 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →IRulya Therapeutics Inc. — Overview & Financial Snapshot
IRulya Therapeutics Inc. (NasdaqCM: IRLA) is a Healthcare company, ranked #6,432 of 6,774 companies globally and #3,695 of 4,000 in United States on PositoAI, with a Positivity Score of -19,359. Its market capitalisation is ₹315.17 Cr ($33.39M), P/E ratio is -0.2 and P/B ratio is -0.95. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 4/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →